We Are Crinetics

Crinetics is a pharmaceutical company that researches, discovers, and develops breakthrough therapies for patients with rare endocrine diseases or tumors. We foster long-term relationships with healthcare practitioners to learn intimately about the challenges patients face every day, then focus on developing game-changing therapies that improve their lives in significant ways.

Scientific Poster

CRN04894: An Oral, Nonpeptide ACTH (MC2) Receptor Antagonist Decreased Basal and Stimulated Cortisol Secretion in Healthy Volunteers

Peter J. Trainer, MD; Christine T. Ferrara-Cook, MD, PhD; Alejandro Ayala, MD; Rosa Luo, MS; Stephanie Miller, BA; Yang Wang, MSPH; Martha Hernandez-Illas, MD; R. Scott Struthers, PhD; Stephen F. Betz, PhD; Alan Krasner, MD

Oral Presentation

Long-term efficacy and safety of oral, once daily paltusotine treatment in acromegaly: Two-year interim results from the ACROBAT Advance study

Programme Code: OC3.3
Session Name: Oral Communications 3: Reproductive and Neuroendocrinology
Session Date: Monday 14 November 2022
Session Time: 15:05 – 16:35
Order in Session: 3 of 6

peter trainer, vice president, clinical endocrinology

Presented by: Peter Trainer

CONTACT US

Please fill out the information below and our medical affairs team will reach out to you about Crinetics and our Phase 2 and future Phase 3 studies with paltusotine for the treatment of carcinoid syndrome.

An Entire Pipeline of Progress

Intellectual rigor, sound science, and innovative approaches are the hallmarks of our work and the way we maintain a healthy pipeline.

We focus on the discovery of drugs for rare endocrine disease and related tumors with:

  • High unmet medical need
  • Established biology
  • Biomarker endpoints
  • Early phase POC
  • Efficient registration trials
View Pipeline >
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Atumelnant (Oral ACTH Antagonist)
Congenital Adrenal Hyperplasia (CAH)
ACTH-dependent Cushing's syndrome
PTH Antagonist, Hyperparathyroidism
SST3 Agonist, Polycystic Kidney Disease
TSH Antagonist, Graves' Disease, TED
Oral GLP-1 nonpeptide, Diabetes, Obesity
Oral GIP nonpeptide, Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Atumelnant (Oral ACTH Antagonist)
Congenital Adrenal Hyperplasia (CAH)
ACTH dependent Cushing's syndrome
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company